NCT03381352

Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer

Phase II Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 27 (estimated)
• Sponsor: Chinese Academy of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and adverse events of intensity modulated radiation therapy (IMRT) concurrent with chemotherapy for anal squamous carcinoma. All enrolled anal squamous carcinoma patients are intented to receive IMRT concurrent with Capecitabine + mitomycin ± cetuximab targeted therapy.

Conditions

• Anal Cancer

Interventions

Type	Name	Description
RADIATION	Chemo-radiotherapy with IMRT technique	IMRT radiation technique; 50.4-54Gy/25F
DRUG	Capecitabine	Capecitabine 825mg/m2 PO BID
DRUG	Mitomycin C	Mitomycin C 10mg/m2 D1,29 iv

Timeline

• Start date: 2015-12-02
• Primary completion: 2018-12-31
• Completion: 2020-12-31
• First posted: 2017-12-22
• Last updated: 2018-01-30

Locations

1 site across 1 country: China